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Background: Immunological arguments and historical examples have shown that treatment with cord blood for
non-hematopoietic activities, such as growth factor production and stimulation of angiogenesis, may not require
matching or immune suppression.
Methods: To study the benefit of blood mononuclear cell therapy, 8 patients with idiopathic osteoporosis were
given intermittent treatments with non-matched allogeneic cord blood mononuclear cells for 3 months. Morning
fasting samples were collected for measuring urine N telopeptide of type-1 collagen, serum bone-specific alkaline
phosphatase, and insulin-like growth factor 1 during one-year study.
Results: Clinical response was striking. Serum insulin-like growth factor 1 significantly increased in all patients at
3 months compared with baseline values, from 264.1 ± 107.0 to 384.4 ± 63.1 ng/mL (P= 0.002), with a tendency to
return to baseline values at 12 months (312.9 ± 75.5 ng/mL, P= 0.083). In contrast, differences in serum bone-
specific alkaline phosphatase and urine N telopeptide of type-1 collagen were not significant at 3 (P= 0.765,
P= 0.057) or 12 months (P= 0.889, P= 0.122). A beneficial effect on bone density was observed in all patients at the
lumbar spine. The mean bone mineral density calculated during therapy (0.6811 ± 0.1442 g/cm2) tended higher
than baseline values (0.6239 ± 0.1362 g/cm2, P< 0), and percentage change (median) varied from 8.85% at
3 months to 7.85% at one year. All patients are now well after one year.
Conclusions: The findings indicate that for these patients with idiopathic osteoporosis, treatment with cord blood
mononuclear cells led to a significant increase in insulin-like growth factor 1 levels, which favors the increase in
bone mineral density.
Keywords: Osteoporosis, Cord blood mononuclear cellsBackground
Idiopathic osteoporosis is a rare condition that affects
both sexes, women before menopause and men up to
sixty-five years. Patients have a decreased ability to re-
cover or regenerate bone mineral content, which may
result in bone fracture with little trauma. Diagnosis
requires the exclusion of all potential causes of second-
ary osteoporosis. Asian people on average have a lower
bone mineral density than other races, yet their bones* Correspondence: lijun199766@126.com
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reproduction in any medium, provided the orfracture less easily; human races also differ in the refer-
ence values of bone turnover biomarkers.
Inadequate peak bone mass [1] and increased bone
loss are probably involved in the pathogenesis of idio-
pathic osteoporosis [2]. Both phenomena are associated
with low concentrations of insulin-like growth factor 1
in serum [3,4] and bone [5]. The causes of low serum
insulin-like growth factor 1 levels in patients with idio-
pathic osteoporosis remain unclear.
Bone regeneration process involving mesenchymal stem
cell invasion, chondrogenesis, osteogenesis, and angiogen-
esis, breaks down during idiopathic osteoporosis. Circulat-
ing multipotent stem cells with characteristic ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for osteoporosis [6]. Cord blood mononuclear cells consist
of hematopoietic and mesenchymal stem cells, endothelial
progenitor cells, and immature immunological cells [7].
Preclinical studies have demonstrated the efficacy of cord
blood in the treatment of diverse conditions including
amyotrophic lateral sclerosis [8], type I diabetes [9], post-
infarct regeneration [10], liver failure [11], and cerebral
palsy [12]. Under the practice of medicine, some treatment
facilities have been using cord blood stem cells without
matching [13-17]. In immune competent recipients, non-
matched allogeneic cord blood cells do not elicit graft ver-
sus host disease [18-23].
The mesenchymal content of cord blood may explain
the tolerogenic capabilities. Cord blood-derived mesen-
chymal stem cells secrete immune inhibitory cytokines
including IL-10 and TGF-β [24,25]. Lymphocytes from
cord blood, in contrast to adult blood, are generally im-
mature and usually do not secrete as many inflammatory
cytokines [18].
For non-hematopoietic applications, the therapeutic
activities of the cord blood are mediated by paracrine ef-
fect [26]. In these situations permanent graft survival
and matched cells are not essential[17]. The aim of this
study is to investigate the benefits of intermittent sub-
cutaneous injections of non-matched allogeneic cord
blood mononuclear cells in patients with idiopathic
osteoporosis, by evaluating bone density.Methods
Patient characteristics
No prisoner or organs from a prisoner were used in the
study. Eight Han Chinese patients (2 men and 6 women,
36–53 years old) with idiopathic osteoporosis were
included in this study, selected patients seen at Kunming
General Hospital of Chinese People's Liberation Army.
The osteoporosis was considered idiopathic after exten-
sive clinical and laboratory investigation that excluded
endocrine disorders and other chronic diseases that
could cause bone loss. All men and three women had
previous fragility fractures at the time of diagnosis, while
the others were considered osteoporotic on bone densi-
tometry. All patients were in stable clinical condition at
the time of the study, without 1) prior history of severeTable 1 Summary of clinical history and the first densitometr
P1 P2
sex and age at study (years) M, 53 M, 41




age at first densitometry (years) 51 40
LS BMD at first densitometry (g/cm2) 0.722 0.617
P: Patient, M: male, F: female, LS: lumbar spine; BMD: bone mineral density.allergic reactions; 2) history of, or active, malignancy; 3)
active systemic or severe focal infections; 4) cardiac, pul-
monary, renal, hepatic or gastrointestinal disease; 5) psy-
chiatric disorder; or 6) any immunodeficiency disease or
condition (as these could influence the prognosis and
end-point measurements).
The patients received conventional treatments without
increase in bone mineral density ≥ 1 year prior to enter-
ing the current study. They were treated from December
2010 to January 2012 at Kunming General Hospital of
Chinese People's Liberation Army. The local institu-
tional review board of Kunming General Hospital of the
Chinese People's Liberation Army, under the auspices of
the National Ministry of Heath, approved application of
the technique. Each patient signed an informed consent
form before initiation of treatment. A summary of
patients’ clinical history and the results of the first bone
density are shown in Table 1.Cell processing
Umbilical cord blood was collected from healthy unre-
lated full-term uterine-incision delivery donors (who
provided written informed consent) in accordance with
the sterile procurement guidelines for cord blood. After
collection, each blood sample was tested and verified
free of communicable diseases including the hepatitis B
and C viruses (HBV and HBC, respectively), human im-
munodeficiency virus (HIV), alanine aminotransferase
(ALT), and syphilis. Testing was performed by a third
party laboratory under local government-monitored con-
ditions. Then 2–3 blood samples were mixed together.
Twenty-five milliliters of cord blood was added to
25 mL of Ficoll-Paque PREMIUM 1.073 (GE Healthcare
AB, Uppsala, Sweden, http://www.amersham.com) in
every 50 mL centrifuge tube and then centrifuged (750 g,
25 min). Mononuclear cells were collected and washed
twice in saline. Contaminating erythrocytes were lysed
with lysis buffer consisting of injection grade water. The
cells were sieved through a 100 eye cell sieve mesh be-
fore administration and were injected as quickly as pos-
sibly after preparation (cell number ≥6 × 107, containing
0.5% CD34+ cells, 0.2% CD11b+ cells, 9.7% CD4+ cells,
and 8.6% CD14+ cell as determined by flow cytometry;
cell viability ≥96%).y data
P3 P4 P5 P6 P7 P8





no no since age 33,
left humerus
no
33 36 38 41 41 34
0.730 0.665 0.589 0.578 0.424 0.608
Table 2 Individual values of insulin-like growth factor 1
(ng/mL) along the therapy
Baseline 3 months 1 year
IGF-1 (ng/ml) *
Patient 1 (male) 286 372 390
Patient 2 (male) 277 388 286
Patient 3 (male) 183 306 232
Patient 4 (male) 365 446 359
Patient 5 (male) 406 489 428
Patient 6 (male) 89 371 280
Patient 7 (male) 177 304 212
Patient 8 (male) 330 399 316
* p= 0.002 comparing 3 months to baseline, p= 0.083 comparing 1 year to
baseline.
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Each patient was treated intermittently with 6 × 107
cells/dose, at 4-weeks intervals, 4 times in total, with a
follow-up period of 12 months. Twenty milliliters of cell
suspension in saline solution (6 × 107 cells/20 mL) were
subcutaneously injected in several places in the left arm
of every patient for convenient observation over 10 to 20
minutes. Injection was repeated 4 times, treatments were
separated at 4 week-intervals, and each time with differ-
ent baby-derived cord blood cells (each time with 2–3
cord blood cell samples for every patient). All patients
received 10 samples of cord blood cells in total. After
each dose, patients were asked if they experienced dis-
comfort or improvement of syndrome before administer-
ing the next dose. No patient received any other
medicine, to avoid an interference effect during the ther-
apy schedule (the entire year).
Routine test, insulin-like growth factor 1, bone-specific
alkaline phosphatase, N telopeptide of type-1 collagen
and bone mineral density measurements
Patients returned monthly for clinical examination that
included blood pressure and body weight measurements.
Blood was drawn after overnight fasting for routine tests.
Serum calcium, phosphate, parameters of liver function,
lipids, and blood glucose were measured via automated
techniques. Fasting morning serum samples were col-
lected for serum insulin-like growth factor 1 and bone-
specific alkaline phosphatase, and a sample of the sec-
ond voided urine was collected for evaluation of the N-
telopeptide of type-1collagen at baseline, 3 months and
12 months after the initial treatment. Concentration of
insulin-like growth factor 1 was measured with the kit
DSL 5600 ACTIVE, EUA. Bone-specific alkaline phos-
phatase was measured with the kit Alkphaseb, USA.
Urinary N-telopeptide of type-1collagen was measured
with the kit Osteomark, USA.
Bone mineral density was measured at the lumbar
spine using dual-energy X-ray absorptiometry (Expert,
Lunar, Madison, WI, USA) at baseline, 3 months and
1 year after the initial treatment. Percent variations in
bone mineral density ≥1.5% at the lumbar spine were
considered significant. Statistical analysis was performed
using the software IBM SPSS 18.0. One-way ANOVA for
repeated measures and the paired t-test were used to
evaluate the differences between levels at baseline and at
3 months, and between baseline and at 1 year. P-values
< 0.05 were considered significant.
Results
Analysis of overall effect for a one year follow-up (begin-
ning with the first administration) showed that treat-
ment with cord blood mononuclear cells via
subcutaneous injections was well-tolerated. No allergicor immunological reactions, graft-versus-host disease, or
serious adverse effects were observed at the time of in-
jection or while under observation. All patients were free
of communicable diseases such as HBV, HCV, HIV, ALT,
and syphilis at 3 months. None of the patient had to be
withdrawn from the study. Blood pressure and body
mass index did not change, nor did the parameters of
renal and hepatic functions, serum calcium, phosphate
and lipids.
Serum insulin-like growth factor 1 increased in all
patients and remained above baseline values during treat-
ment. The mean insulin-like growth factor 1 calculated
during the therapy (348.6± 66.9 ng/mL) tended to be
higher than baseline values (264.1± 107.0 ng/mL,
P=0.008). The mean serum insulin-like growth factor 1
increased at 3 months from 264.1 ± 107.0 to
384.4± 63.1 ng/mL (P=0.002) and tended to return to
baseline values at 1 year (312.9 ± 75.5 ng/mL, P=0.083).
The difference in serum insulin-like growth factor 1 at
3 months and 1 year of the therapy schedule was also sig-
nificant (P=0.001). Individual values are shown in Table 2.
The mean serum bone-specific alkaline phosphatase
levels did not change remarkably: it increased from
16.2 ± 8.0 U/L at baseline to 16.5 ± 6.3 U/L at 3 months,
and to 15.9 ± 4.2 U/L at 12 months, but the variations
were not significant (P= 0.765, P= 0.889, respectively).
The mean urine N telopeptide of type-1 collagen
decreased from 16.8 ± 4.3 nMBCE/mMCr at baseline to
13.8 ± 2.4 nMBCE/mMCr at 3 months, and tended to re-
turn to baseline values at 12 months (14.8 ± 4.0 nMBCE/
mMCr), but variations were not significant (P= 0.057,
P= 0.122, respectively).
Absolute values of bone mineral density at baseline,
3 months and 1 year are shown in Table 3. A beneficial ef-
fect on bone density was observed in all of the patients at
the lumbar spine with therapeutic schedules of treatment
after either 3 or 12 months, and percentage change (me-
dian) varied from 8.85% at 3 months to 7.85% at one year.
Table 3 Variation and percent change in lumbar spine
bone mineral density (g/cm2)
P 1 P 2 P 3 P 4 P 5 P 6 P 7 P 8
(M) (M) (F) (F) (F) (F) (F) (F)
LS BMD (g/cm2)
at baseline
0.707 0.611 0.790 0.623 0.784 0.455 0.423 0.598
LS BMD (g/cm2)
at 3 months
0.761 0.668 0.884 0.650 0.846 0.493 0.495 0.672
LS BMD (g/cm2)
at 1 year
0.749 0.660 0.879 0.650 0.844 0.488 0.491 0.667
% change LS BMD
at 3 months
7.6 9.3 11.9 4.3 7.9 8.4 17.0 12.4
% change LS BMD
at 1 year
5.9 8.0 11.3 4.3 7.7 7.3 16.1 11.5
Effect on LS BMD + + + + + + + +
P: Patient, (M): male, (F): female, LS: lumbar spine, BMD: bone mineral density,
+: positive. The effect of cord blood mononuclear cells was considered as
positive when the increase in bone mineral density was bigger than 1.5% at
lumbar spine or when patients stopped loosing bone.
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the bone density after therapy was compared with that at
baseline (Figure 1). The mean bone mineral density calcu-
lated during the therapy (0.6811± 0.1442 g/cm2) tended to
be higher than baseline values (0.6239± 0.1362 g/cm2, P
< 0). The mean bone mineral density varied from
0.6239± 0.1362 at baseline to 0.6836± 0.1444 (P< 0) at
3 months and tended to return to baseline values at 1 year
(0.6785± 0.1441, P< 0); the variation in bone density from
3 months to 1 year of the therapy schedule was also sig-
nificant (P=0.005). The effect of cord blood mononuclear
cells was positive in all patients at the lumbar spine, as
showed a net variation of> 1.5%.
Discussion
Although cord blood-derived cells are superior to bone
marrow in terms of growth factor production ability,
pluripotency, and immune modulating activity [27], their
use has been limited to autologous sources forA
Figure 1 The lumbar spine (L2-L4) bone mineral density of patient 7
patient 7 at baseline. B, The lumbar spine (L2-L4) bone mineral density of p
density of patient 7 at 1 year.regenerative applications [17]. In the present study we
administrated the latest extracted cells without any other
medicine to avoid their interference effect during the
whole year. No graft versus host disease or adverse
effects were observed after treatment. All patients were
free of communicable diseases such as HBV, HCV, HIV,
ALT, and syphilis at 3 months. We believe that cord
blood mononuclear cells are a viable alternative source
of stem cells as they are safely applicable without signifi-
cant adverse effects.
All patients had a net bone gain of> 1.5% at the lum-
bar spine with the therapy in the current study. The var-
iations in serum bone-specific alkaline phosphatase and
urine N telopeptide of type-1 collagen were not signifi-
cant at 3 or 12 months. However, the mean urine N telo-
peptide of type-1 collagen decreased at 3 months and
tended to return to baseline values at 12 months
(P= 0.057, P= 0.122). The variations in bone turnover
marker during therapy usually take place far earlier than
those of the bone density. The time points of 3 months
and 12 months and the small sample size in this study
may contribute to the negative result for N telopeptide
of type-1 collagen; and the serum bone-specific alkaline
phosphatase levels did not change remarkably, indicating
that the possible effect of cord blood mononuclear cells
is primarily antiresorptive.
We maintained cord blood mononuclear cells during
the first 3 months of therapy. The monthly dose of 6 × 107
cord blood mononuclear cells increased insulin-like
growth factor 1 levels in all patients at 3 months, and
eventual supernormal levels were sustained after 1 year, al-
though the difference at 12 months was not significant.
The maintenance of insulin-like growth factor 1 concen-
trations in the blood correlated with bone density increase
in response to cord blood mononuclear cell therapy.
Insulin-like growth factor 1 influenced the effect of cord
blood mononuclear cells on bone. The data suggest that
cord blood mononuclear cells contributed to the increaseB C
at baseline. A, The lumbar spine (L2-L4) bone mineral density of
atient 7 at 3 months. C, The lumbar spine (L2-L4) bone mineral
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during the treatment, thus favoring bone mineral density
increase. Insulin-like growth factor 1 response to cord
blood mononuclear cells probably contributed to the
normalization of bone formation. It initializes bone re-
modeling cycles with a relatively greater enhancement of
bone density, probably explaining the further increase in
bone density observed in this study after stopping cord
blood mononuclear cells in patients with idiopathic osteo-
porosis. As a consequence, the expected beneficial effect
of cord blood mononuclear cells on bone density already
was evident after the first year.
The difference in bone density between 3 months and
1 year of the therapy schedule was significant (P= 0.005).
An attenuated positive effect on lumbar spine bone dens-
ity was seen after 1 year, as insulin-like growth factor 1
was maintained above baseline values, although the differ-
ence in insulin-like growth factor 1 between baseline and
1 year was not significant. Thus, it is possible that our
patients will continue to decrease bone density in the fol-
lowing year.
Although cord blood stem cells can differentiate into
diverse cell lineages [28], the injected cells stimulate the
intrinsic stem cells to help them proliferate and differen-
tiate [29]. Not the replacement of injured tissue by
transdifferentiation of stem cells, but the paracrine effect
promotes the regeneration of damaged tissue [30,31].
We assume that the paracrine effect mainly contributed
to our patient’s improvements in this study.
Clinical effect of cord blood transplantation depends
on the mononuclear cells number, but most cord blood
samples do not contain enough stem cells. Increasing
cell dose improves engraftment, and partially surmount
the influence of human leukocyte antigen disparities.
Since 2005, the number of adult patients transplanted
with double umbilical cord blood has surpassed the
number of adults receiving single cord blood units [32].
In this study we injected the cord blood mononuclear
cells expecting transient engraftment and stimulation
(paracrine) activity. We administrated the cells from a
mixture of several blood samples to guarantee the en-
graftment of stem cells [33,34]. At least 6 × 107 cells
were given each time, enough for cell transplantation,
and at the same time we administrated the intermittent
treatment with 6 × 107 cells/dose for safe opinion. The
repeated administration (4 times) maintained the sur-
vival of enough of the stem cells in the patients’ bodies.
The prolonged infusion intervals (4 weeks) can prevent
immune responses induced by repeated administration.
Some studies demonstrated that stem cell therapy can
result in functional improvement of the damaged organs
in long term period [35,36]. Although we cannot guaran-
tee the longer term effect from our study alone, the
results from this long term study are encouraging. Onelimitation of this study is the small sample size, but idio-
pathic osteoporosis is an uncommon disease. The other
limitation is the absence of a placebo-treated control
group. However, the patients received conventional
treatments without significant increase in bone mineral
density prior to entering the current study. In addition,
the effect of cord blood mononuclear cells can be con-
sidered positive when the increase in bone mineral dens-
ity is greater than 1.5% at the lumbar spine, or when
patients stop losing bone. For this purpose, each patient
could be considered as his own control.
Conclusion
Our data suggest that intermittent administration of
non-matched allogeneic cord blood mononuclear cells
therapy exerts beneficial effects on bone mineral density
in patients with idiopathic osteoporosis. Insulin-like
growth factor 1 initializes bone remodeling cycles with a
greater enhancement of bone density, probably explain-
ing the increase in bone density observed in this study.
The importance of this study is that it is the first to in-
vestigate the effects of non-matched allogeneic cord
blood mononuclear cells on bone mineral density in
patients with idiopathic osteoporosis, and the positive ef-
fect is encouraging. More studies using this regimen for
longer periods are needed to further define the effects of
cord blood mononuclear cells on bone density and frac-
ture risk in patients with idiopathic osteoporosis.
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